The influence of ACEA - A selective cannabinoid CB1 receptor agonist on whole blood and platelet-poor plasma serotonin concentrations

Pharmazie

Volumn 64, Issue 9, 2009, Pages 598-601

  Rutkowska, Maria ^a   Gliniak, H ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ARACHIDONYL 2 CHLOROETHYLAMIDE; CANNABINOID 1 RECEPTOR AGONIST; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL TRACT; MALE; NONHUMAN; RAT; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE; THROMBOCYTE POOR PLASMA;

ANIMALS; ARACHIDONIC ACIDS; BLOOD PLATELETS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MALE; PIPERIDINES; PLASMA; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SEROTONIN;

EID: 75749089287     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.9608     Document Type: Article

References (43)

1. Baldassarri S, Bertoni A, Bagarotti A, Sarasso C, Zanfa M, Catani MV, Avigliano L, Maccarrone M, Torti M, Sinigaglia F (2008) The endocannabinoid 2-arachidonoylglycerol activates human platelets through non-CB1/CB2 receptors. J Thromb Haemost 6: 1772-1779.
2. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083-1152.
3. Beattie DT, Smith JA (2008) Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol 377: 181-203.
4. Coffman JD, Cohen RA (1994) Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenon. Clin Sci (Lond) 86: 269-273.
5. Coutts AA, Izzo AA (2004) The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol 4: 572-579.
6. Dempsie Y, MacLean MR (2008) Pulmonary hypertension: therapeutic targets within the serotonin system. Br J Pharmacol 155: 455-562.
7. Deusch E, Kress HG, Kraft B, Kozek-Langenecker SA (2004) The procoagulatory effects of D9-tetrahydrocannabinol in human platelets. Anesth Analg 99: 1127-1130.
8. Doggrell SA (2003) The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Expert Opin Investig Drugs 12: 805-823.
9. Duncan M, Davison JS, Sharkey KA (2005) Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 22: 667-683.
10. Ellis ES, Byrne C, Murphy OE, Tilford NS, Baxter GS (1995) Mediation by 5-hydroxytryptamine2B receptors of endothelium-dependent relaxation in rat jugular vein. Br J Pharmacol 114: 400-404.
11. Formokong EA, Evans AT, Evans FJ (1989) The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and rabbit platelet aggregation. J Pharm Pharmacol 41: 705-709.
12. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Anti-depressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102: 18620-18625.
13. Hannon J, Hoyer D (2008) Molecular biology of 5-HT receptors. Behav Brain Res 195: 198-213.
14. Hill MN, Gorzalka BB (2005) Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in rat forced swim test. Eur Neuropsychopharmacol 15: 593-599.
15. Hoyer D, Hannon JP, Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533-554.
16. Hu DL, Zhu G, Mori F, Omoe K, Okada M, Wakabayashi K, Kaneko S, Shinagawa K, Nakane A (2007) Staphylococcal enterotoxin induces emesis through increasing serotonin release in intestine and it is downregulated by cannabinoid receptor 1. Cell Microbiol 9: 2267-2277.
17. Izzo AA, Camilleri M (2008) Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects Gut 57: 1140-1155.
18. 7 receptor-mediated relaxation in pulmonary arteries of weaned pigs. Naunyn Schmiedebergs Arch Pharmacol 371: 89-98.
19. Kim DY, Camilleri M (2000) Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 95: 2698-2709.
20. Lesch KP, Wolozin BL, Murphy DL, Reiderer P (1993). Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 60: 2319-2322.
21. Levy R, Schurr A, Nathan I, Dvilanski A, Livne A (1976) Impairment of ADP-induced platelet aggregation by hashish components. Thromb Haemost 36: 634-640.
22. Maccarrone M, Bari M, Menichelli A, Del Principe D, Finazzi-Agrò A (1999) Anandamide activates human platelets through a pathway independent of the arachidonate cascade. FEBS Lett 447: 277-282.
23. Maccarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi-Agrò A (2001) Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem 266: 819-825.
24. Maccarrone M, Bari M, Principe DD, Finazzi-Agrò A (2003) Activation of human platelets by 2-arachidonoylglycerol is enhanced by serotonin. Thromb Haemost 89: 340-347.
25. Martin GR, Humphrey PP (1994) Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology 33: 261-273.
26. Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T (2004) Functions of 5-HT2A receptor and its antagonist in the cardiovascular system. Pharmacol Ther 104: 59-81.
27. Nakamura K, Kariyazono H, Masuda H, Sakata R, Yamada K (2001) Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans. Blood Coagul Fibrinolysis 12: 391-397.
28. Ni W, Watts SW (2006) 5-Hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol 33: 575-583.
29. Nishihira K, Yamashita A, Tanaka N, Kawamoto R, Imamura T, Yamamoto R, Eto T, Asada Y (2006) Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J Thromb Haemost 4: 247-255.
30. Ortiz J, Artigas F (1992) Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine. Br J Pharmacol 105: 941-946.
31. Pietraszek MH, Choudhury NA, Baba S, Sakaguchi S, Hachiya T, Urano T, Takada Y, Takada A (1993) Serotonin as a factor involved in pathophysiology of thromboangiitis obliterans. Int Angiol 12: 9-12.
32. Ramage AG, Villalón CM (2008) 5-Hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci 29: 472-481.
33. Randall MD (2007) Endocannabinoids and the haematological system. Br J Pharmacol 152: 671-675.
34. Robertson JI (1991) Serotonergic type-2 (5-HT2) antagonists: a novel class of cardiovascular drugs. J Cardiovasc Pharmacol 17 (Suppl 5): S48-S53.
35. Rydzewski A, Urano T, Hachiya T, Kaneko H, Baba S, Takada Y, Takada A (1996) The effect of a 5-HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb Res 84: 445-452.
36. Sanger GJ (2008) 5-Hydroxytryptamine and the gastrointestinal tract: where next? Trends Pharmacol Sci 29: 465-471.
37. Schoeffter P, Hoyer D (1990) 5-Hydroxytryptamine (5-HT)-induced endothelium-dependent relaxation of pig coronary arteries is mediated by 5-HT receptors similar to the 5-HT1D receptor subtype. J Pharmacol Exp Ther 252: 387-395.
38. Spiller RC (2001) Effects of serotonin on intestinal secretion and motility. Curr Opin Gastroenterol 17: 99-103.
39. Takada Y, Ihara H, Urano T, Takada A (1995) Changes in blood and plasma serotonergic measurements in rats-effect of nicotine and/or exposure to different stresses. Thromb Res 80: 307-316.
40. Velenovská M, Fisar Z (2007) Effect of cannabinoids on platelet serotonin uptake. Addict Biol 12: 158-166.
41. Villalón CM, Centurión D (2007) Cardiovascular responses produced by 5-hydroxytryptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol 376: 45-63.
42. Volfe Z, Dvilansky A, Nathan I (1985) Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharm 5: 243-246.
43. Żołtowski R, Pawlak R, Matys T, Pietraszek M, Buczko W (2002) Propranolol modifies platelet serotoninergic mechanisms in rats. J Physiol Pharmacol 53: 265-274.